SLGL
NASDAQSol-Gel Technologies Ltd.
Price$77.31-0.09 (-0.12%)
02:30 PM05:15 PM
News · 26 weeks40+100%
2025-12-142026-06-07
Mix2890d
- Insider14(50%)
- Other9(32%)
- SEC Filings4(14%)
- Analyst1(4%)
Latest news
25 items- ANALYSTTD Cowen initiated coverage on Sol-GelTD Cowen initiated coverage of Sol-Gel with a rating of Buy
- SECSEC Form 6-K filed by Sol-Gel Technologies Ltd.6-K - Sol-Gel Technologies Ltd. (0001684693) (Filer)
- PRSol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesSol-Gel received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044Sol-Gel completed an oversubscribed underwritten offering, raising gross proceeds of approximately $33.1 million from leading healthcare specialist investorsPivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in the fourth quarter of 2026Sol-Gel signed an exclusive license agreement with Sun Pharmaceutical Industries Ltd. for the commercialization of TWYNEO® in India NESS ZIONA, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies,
- INSIDERLarge owner Opaleye Management Inc. bought $100,712 worth of Ordinary Shares (1,563 units at $64.43) (SEC Form 4)4 - Sol-Gel Technologies Ltd. (0001684693) (Issuer)
- INSIDERLarge owner Opaleye Management Inc. bought $231,502 worth of Ordinary Shares (3,437 units at $67.36) (SEC Form 4)4 - Sol-Gel Technologies Ltd. (0001684693) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Sol-Gel Technologies Ltd.SCHEDULE 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Sol-Gel Technologies Ltd.SCHEDULE 13D/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)
- SECSEC Form SCHEDULE 13G filed by Sol-Gel Technologies Ltd.SCHEDULE 13G - Sol-Gel Technologies Ltd. (0001684693) (Subject)
- SECSEC Form 6-K filed by Sol-Gel Technologies Ltd.6-K - Sol-Gel Technologies Ltd. (0001684693) (Filer)
- SECSEC Form 424B5 filed by Sol-Gel Technologies Ltd.424B5 - Sol-Gel Technologies Ltd. (0001684693) (Filer)
- INSIDERSEC Form 4 filed by Opaleye Management Inc.4 - Sol-Gel Technologies Ltd. (0001684693) (Issuer)
- SECSEC Form EFFECT filed by Sol-Gel Technologies Ltd.EFFECT - Sol-Gel Technologies Ltd. (0001684693) (Filer)
- PRSol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten OfferingNESS ZIONA, Israel, March 23, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the "Company") (NASDAQ:SLGL) today announced the pricing of an underwritten offering of 459,112 ordinary shares (the "Shares") at a price of $72.00 per Share, resulting in gross proceeds to the Company, before deducting underwriting discounts and commissions and other estimated offering expenses, of approximately $33.1 million. All of the Shares are to be sold by the Company. The offering is expected to close on or about March 25, 2026, subject to satisfaction of customary closing conditions. The offering included participation from new and existing investors, including Great Point Partners, LLC, Trails Edge
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Sol-Gel Technologies Ltd.SCHEDULE 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)
- SECSEC Form POS AM filed by Sol-Gel Technologies Ltd.POS AM - Sol-Gel Technologies Ltd. (0001684693) (Filer)
- PRSol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025NESS ZIONA, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the "SEC"). The annual report on Form 20-F, which contains Sol-Gel's audited annual financial statements for 2025, can be accessed on the SEC's website at http://www.sec.gov, as well as via the Company's investor relations website at https://ir.sol-gel.com/financials/sec-filings. The Company will deliver a hard copy of its 2025 annual report on Form 20-F, including its complete audited financial statements, free of charge to its sharehold
- SECSEC Form 20-F filed by Sol-Gel Technologies Ltd.20-F - Sol-Gel Technologies Ltd. (0001684693) (Filer)
- INSIDERSEC Form 3 filed by new insider Ben-Or Eyal3 - Sol-Gel Technologies Ltd. (0001684693) (Issuer)
- INSIDERSEC Form 3 filed by new insider Yosef Itzik3 - Sol-Gel Technologies Ltd. (0001684693) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gottfried Ran3 - Sol-Gel Technologies Ltd. (0001684693) (Issuer)
- INSIDERSEC Form 3 filed by Sol-Gel Technologies Ltd.3 - Sol-Gel Technologies Ltd. (0001684693) (Issuer)
- INSIDERSEC Form 3 filed by new insider Yanai Yuval3 - Sol-Gel Technologies Ltd. (0001684693) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lerman Hanna3 - Sol-Gel Technologies Ltd. (0001684693) (Issuer)
- INSIDERSEC Form 3 filed by new insider Arkin Itai Gidon3 - Sol-Gel Technologies Ltd. (0001684693) (Issuer)
- INSIDERSEC Form 3 filed by new insider Glezin Michael3 - Sol-Gel Technologies Ltd. (0001684693) (Issuer)
SLGL FAQ
7 questionsWhat does Sol-Gel Technologies Ltd. do?
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the...Where does SLGL stock trade?
Sol-Gel Technologies Ltd. (SLGL) is listed on NASDAQ.What sector and industry is SLGL in?
Sol-Gel Technologies Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Sol-Gel Technologies Ltd. go public?
Sol-Gel Technologies Ltd. (SLGL) completed its IPO in 2018.What are analysts saying about SLGL?
Sol-Gel Technologies Ltd. has had 7 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2026-05-29.What companies are similar to SLGL?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SLGL side-by-side with any of them on Quantisnow.How can I track SLGL on Quantisnow?
Quantisnow aggregates Sol-Gel Technologies Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SLGL to receive live email and push alerts on every new disclosure.